Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $464 from $462 and keeps an Equal Weight rating on the shares. Vertex reported a Q1 miss, but raised the lower end of 2025 revenue guidance by $100M to $11.85B-$12B, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Optimistic Outlook for Vertex Pharmaceuticals Driven by Strong Market Penetration and Strategic Clinical Advancements
- Cautious Hold Rating for Vertex Pharmaceuticals Amid Mixed Performance and Future Challenges
- Vertex Pharmaceuticals price target raised to $423 from $420 at RBC Capital
- Vertex Pharmaceuticals: Strong Growth Prospects and Strategic Positioning Support Buy Rating Despite Q1 Miss
- Vertex Pharmaceuticals: Hold Rating Amid Revenue Misses and Strategic Outlook